# Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines

> **NCT05292638** · PHASE1 · COMPLETED · sponsor: **CKD Bio Corporation** · enrollment: 30 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** CKDB-501A
- **DRUG:** Botox®

## Key facts

- **NCT ID:** NCT05292638
- **Lead sponsor:** CKD Bio Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2022-06-10
- **Final completion:** 2022-06-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05292638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05292638, "Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT05292638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*